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Abstract
Background: PKCh is a novel protein kinase C isozyme, predominately expressed in T cells and platelets. PKCh2/2 T cells
exhibit reduced activation and PKCh2/2 mice are resistant to autoimmune disease, making PKCh an attractive therapeutic
target for immune modulation. Collagen is a major agonist for platelets, operating through an immunoreceptor-like
signalling pathway from its receptor GPVI. Although it has recently been shown that PKCh positively regulates outside-in
signalling through integrin aIIbb3 in platelets, the role of PKCh in GPVI-dependent signalling and functional activation of
platelets has not been assessed.
Methodology/Principal Findings: In the present study we assessed static adhesion, cell spreading, granule secretion,
integrin aIIbb3 activation and platelet aggregation in washed mouse platelets lacking PKCh. Thrombus formation on a
collagen-coated surface was assessed in vitro under flow. PKCh2/2 platelets exhibited reduced static adhesion and filopodia
generation on fibrinogen, suggesting that PKCh positively regulates outside-in signalling, in agreement with a previous
report. In contrast, PKCh2/2 platelets also exhibited markedly enhanced GPVI-dependent a-granule secretion, although
dense granule secretion was unaffected, suggesting that PKCh differentially regulates these two granules. Inside-out
regulation of aIIbb3 activation was also enhanced downstream of GPVI stimulation. Although this did not result in increased
aggregation, importantly thrombus formation on collagen under high shear (1000 s21) was enhanced.
Conclusions/Significance: These data suggest that PKCh is an important negative regulator of thrombus formation on
collagen, potentially mediated by a-granule secretion and aIIbb3 activation. PKCh therefore may act to restrict thrombus
growth, a finding that has important implications for the development and safe clinical use of PKCh inhibitors.
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Introduction
The protein kinase C (PKC) family critically regulates platelet
activation. Many platelet functional responses, including secretion
and aggregation are reduced or abolished by broad-spectrum
PKC inhibitors and enhanced by PKC activators [1], suggesting a
positive role for the PKC family in general in platelet activation.
However, calcium responses are clearly negatively regulated by
PKC isoforms [2], and we have shown by pharmacological and
genetic approaches that PKCd is a negative regulator of platelet
aggregation by modulating actin dynamics through VASP [3,4].
Individual PKC isoforms therefore play distinct roles, both positive
and negative, during platelet activation, and the effect of broad-
spectrum PKC inhibition or activation reflects a balance of effects
on positive and negative regulatory pathways [1].
Human platelets express predominantly four PKC isoforms: a,
b, d and h. In addition to these, mouse platelets express PKCe [3–
9]. The specific importance of each isoform is hard to assess by
pharmacological approaches owing to the lack of isoform
specificity of these agents. The availability of biochemical and
genetic tools has allowed the functions of specific isoforms to be
addressed. Using such approaches, we and others have recently
demonstrated highly specific roles for individual PKC isoforms in
regulating platelet function: PKCa is critically required for granule
secretion and secretion-dependent aggregation [10,11]; PKCb is
recruited to integrin aIIbb3 and positively regulates outside-in
signalling [12]; PKCd, in contrast, negatively regulates filopodia
formation, and lack of PKCd leads to enhanced platelet
aggregation [13].
PKCh is a novel (i.e. DAG-sensitive, Ca2+-insensitive) PKC
isoform, predominantly expressed in T-cells, muscle cells and
platelets [14,15]. PKCh2/2 mice exhibit reduced T cell activation,
proliferation and IL-2 production downstream of T-cell receptor
stimulation, owing to markedly reduced activation of multiple
transcription factors [16,17] and, as a result, these mice are
resistant to some models of autoimmune disease [18–20]. PKCh
may also regulate fat-induced insulin resistance [21]. Selective
PKCh inhibitors are therefore of great clinical interest [22,23],
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although none of those currently in development have yet become
commercially available.
We have previously shown that PKCh is physically associated
with, and phosphorylated by, the tyrosine kinase, Btk [4].
However, lack of available PKCh-selective inhibitors has curtailed
research on the role of this isoform in human platelets. Shattil and
co-workers have reported PKCh-deficient platelets spread poorly
on fibrinogen, suggesting that PKCh positively regulates outside-in
signalling. In addition, they demonstrated that PKCh does not
regulate platelet activation in response to a Gq/Gi coupled
agonists PAR4 agonist or to ADP [24]. However, this study did
not examine the role of PKCh in collagen-induced platelet
activation.
Given the primary role played by collagen in inducing platelet
activation during the very early stages of thrombosis, and the
parallels between signalling downstream of the collagen receptor
GPVI and that downstream of immunoreceptors, it was now
important to determine the role played by PKCh in collagen-
induced platelet activation and thrombus formation. We report
that PKCh negatively regulates GPVI-dependent a-granule
secretion and integrin aIIbb3 activation and thereby is the only
PKC isoform yet described with this function. Furthermore, loss of
this negative regulation in PKCh2/2 platelets leads to enhanced
thrombus formation under flow in vitro. These results reveal a novel
negative regulatory pathway in platelet activation, and have
relevance to the current clinical and pharmaceutical interest in
PKCh inhibitors.
Methods
Materials
Unless stated, all reagents were from Sigma Aldrich (Poole,
Dorset, U.K.). Cross-linked collagen-related peptide (CRP) was
from Professor Richard Farndale (Biochemistry, University of
Cambridge, U.K.). Horm collagen was from Axis Shield (Bicton,
Cambs., U.K.). Phycoerythrin (PE)-labelled JON/A and fluorescein
isothiocyanate (FITC)-labelled Wug.E9 (anti-P-selectin) antibodies
were from Emfret Analytics (Eibelstadt, Germany). Anti-PKCa, -
PKCb, -PKCd, -PKCe and anti-tubulin antibodies were from BD
Transduction Laboratories (Oxford, U.K). Anti-PKCh antibody
was from Cell Signaling Technology (New England BioLabs,
Hitchin, U.K.). horseradish-peroxidase (HRP)-conjugated anti-
mouse IgG and anti-rabbit IgG secondary antibodies, and
enhanced chemiluminescent (ECL) reagents were from Amersham
(Little Chalfont, Bucks., U.K.). Luciferin-luciferase reagent was
from Chronolog (LabMedics, Manchester, U.K.).
Washed platelet preparation
PKCh2/2 C57BL6/J mice have been described previously
[17]. Wildtype C57BL6/J mice were used as control. Use of
mouse platelets was approved by local research ethics committee
at the University of Bristol, U.K. and mice were bred for this
purpose under UK Home Office licence (PPL 30/2386) held by
AWP. Washed platelets were prepared as previously described
[13]. Of note, platelets were treated with indomethacin (10 mM).
Platelets were rested for 30 min after centrifugation.
Electrophoresis and Western blotting
Washed platelets (26108/ml) were lysed in Laemmli sample
buffer. Proteins were resolved by electrophoresis in 9% SDS-
polyacrylamide gels. Samples were then transferred to polyviny-
lidene difluoride membranes, blocked with 10% bovine serum
albumin, and subjected to immunoblotting with specific antibodies
to various PKC isoforms, as described in the text. Primary
antibody binding was detected by HRP-conjugated secondary
antibodies are revealed using ECL reagents.
Aggregation
Washed platelets (26108/ml) were stimulated by CRP or
collagen in an aggregometer (Chrono-Log, Labmedics, Manche-
ster, U.K.) at 37uC, under continuous stirring at 1000 rpm.
Aggregation was monitored by optical turbidometry.
Dense granule secretion
ATP release from dense granules was monitored using Chrono-
Lume luciferin-luciferase reagent according to the manufacturer’s
instructions.
Analysis of aIIbb3 activation and a-granule secretion by
flow cytometry
Washed platelets (46107/ml) were aliquoted into tubes
containing optimal concentrations of PE-JON/A or FITC-anti-
CD62P, which bind to active integrin aIIbb3 and surface-exposed
P-selectin (CD62P), respectively, and CRP at the final concentra-
tions indicated, for 15 min. Analysis of 20,000 events was
performed using a Becton Dickinson FACScan. The platelet
population as identified by forward and side scatter profile. Data
were analysed using WinMDI version 2.8.
DIC imaging of platelet adhesion and spreading
Measurement of static platelet adhesion and spreading was
performed as previously described [13]. Glass coverslips were
coated with fibrinogen, CRP or collagen and mounted in a live-
cell chamber. Adhesion and spreading of washed platelets (26107/
ml) was followed by differential interference contrast (DIC)
microscopy with a wide-field microscope DM IRB attached to
an ORCA ER camera (63x/1.40 NA oil objective) (Leica
Microsystems, Milton Keynes, UK). Images were processed with
OpenLab 4.03 (Improvision). The surface area of adherent
platelets was measured using Volocity software (Improvision),
while the number of adherent platelets was counted manually.
In vitro thrombus formation
Flow-induced thrombus formation was assessed basically as
described before [25]. A Leica wide-field microscope DM IRB
(63x/1.40 NA oil objective), attached to an ORCA ER camera
was used for image capture (Leica Microsystems, Milton Keynes,
UK). Heparin/PPACK-anticoagulated mouse blood was flowed
over immobilised collagen through a parallel plate perfusion
chamber, at a fixed shear rate of 1000 s21 for 4 minutes. For each
experiment, at least 10 random phase-contrast images were
captured, which were then averaged. Recorded images were
analyzed with ImagePro software.
Statistics
Statistical analyses were performed using GraphPad Prism
software, unless stated otherwise, using two-way ANOVA with
Bonferroni post-test; p,0.05 was considered significant. Bar charts
show mean data6SEM (where ‘n’ denotes the number of
individual mice used).
Results
PKCh2/2 platelets exhibit normal expression of other PKC
isoforms
In order to be confident that any differences seen between
PKCh2/2 and wild-type (WT) platelets were due to loss of PKCh,
PKCq Regulates Platelets
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and not due to altered expression of other PKC isoforms, we
assessed the expression of the major PKC isoforms in platelets by
western blotting. In addition to PKCh, mouse platelets strongly
express PKCa, -b, -d, and -e. No difference in expression of these
isoforms was seen in PKCh2/2 platelets relative to WT platelets
(Fig. 1). The blotting membranes were stripped and re-probed for
a-tubulin, to ensure equal loading of proteins between samples
(Fig. 1, lower panels).
PKCh has a small positive effect on platelet spreading on
fibrinogen
Others have reported that platelet spreading on fibrinogen was
partially defective in PKCh2/2 platelets [24]. We were able to
confirm and extend this result, demonstrating that both adhesion
of platelets and specifically the degree of filopodia generation,
rather than lamellipodia, 45 minutes after static deposition on
fibrinogen-coated coverslips, were reduced in PKCh2/2 platelets
(Table 1). We analysed the kinetics of the spreading process to
determine any further qualitative differences in spreading. Platelets
during/after spreading were scored for number of filopodia and
categorized as having none, few (1 or 2), some (3, 4 or 5) or many
(6 or more) filopodia. The relative frequency of each morphology
was determined and is shown in Fig. 2. 45 minutes after deposition
on the coverslip, most WT platelets had formed at least a few
filopodia, although very few platelets formed lamellipodia,
consistent with other reports [26]. PKCh2/2 mice had a
significantly different distribution of filopodial number, with a
lower proportion forming 6 or more filopodia (p,0.001). As a
consequence, a greater proportion of PKCh2/2 platelets formed
0, 1 or 2 filopodia than WT platelets (p,0.001). Thus, PKCh has
a small, positive regulatory role in filopodia generation on
fibrinogen.
PKCh does not regulate adhesion or spreading on CRP or
collagen
Since PKCh had a role in platelet adhesion and spreading on
fibrinogen, its role in adhesion and spreading on CRP and
collagen was also assessed. CRP is a selective GPVI agonist,
whereas collagen activates both GPVI and integrin a2b1. In
contrast to fibrinogen, no significant effect was seen on adhesion or
total platelet surface area on either of these substrates (Table 1).
Platelet interaction with collagen is therefore not affected by
absence of PKCh.
PKCh negatively regulates CRP-induced platelet
activation
We further investigated whether PKCh regulates platelet
activation following GPVI stimulation. Activation of GPVI leads
to secretion of a-granules and dense granules, and activation of
integrin aIIbb3. The latter is known as inside-out signalling and is
necessary for platelet aggregation.
CRP-induced surface expression of P-selectin, a marker of a-
granule release was enhanced in the absence of PKCh. In WT
platelets, 1 mg/ml CRP induced a 3.160.5 –fold increase over
basal in FITC-P-selectin fluorescence, which was increased to
10.263.0 –fold in PKCh2/2 platelets (n = 8; p,0.05; Fig. 3A),
suggesting that PKCh negatively regulates the release of these
granules. Interestingly, however, no difference in ATP secretion
was seen between PKCh2/2 and WT platelets in response to CRP
(Fig. 3B) or collagen (Fig. 3C).
aIIbb3 activation was determined by flow cytometry using JON/
A, an antibody that recognises the active conformation of this
integrin. Importantly, JON/A binding was almost doubled in
platelets activated by 1 mg/ml CRP, from 3.860.7 –fold over
basal in WT to 7.561.8-fold in PKCh2/2 platelets (n = 8; p,0.05;
Fig. 4A). In contrast, a higher concentration of CRP (5 mg/ml) was
not significantly affected (7.661.2 –fold in WT compared to
Figure 1. PKC isoforms are not upregulated in PKCh2/2 mice. Platelets lysates from wild-type (WT) or PKCh2/2 (KO) mice were assessed for
PKC isoform expression by SDS-PAGE and western blotting using specific antibodies for PKCa, -b, -d, -h and -e. Membranes were stripped and re-
probed for a-tubulin as indicated to ensure equal loading of protein. Blots are representative of three independent experiments.
doi:10.1371/journal.pone.0003277.g001
Table 1. PKCh does not regulate adhesion or spreading on
CRP or collagen.
Adhesion Surface area (mm2)
WT KO WT KO
Fibrinogen 111.164.5 82.7612.0 * 24.961.9 21.660.9 *
CRP 83.767.3 79.662.2 ns 25.861.0 26.561.7 ns
Collagen 130.4634.6 137.2641.8 ns 14.560.6 14.460.8 ns
Platelets were deposited on fibrinogen, CRP or collagen-coated coverslips in a
live-cell chamber for 45 min and visualized by DIC microscopy. Five fields of
view were selected at random and the number of adherent platelets was
counted (adhesion) and spread surface area measured. Adhesion is total
number of platelets adherent to the surface within a single 1000 mm2 field of
view. Shown are combined data from three independent experiments
(mean6SEM; * indicates p,0.05; ns = not significant).
doi:10.1371/journal.pone.0003277.t001
PKCq Regulates Platelets
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10.061.5 –fold in PKCh2/2; n = 8; p = 0.81; Fig. 4A). These data
suggest that PKCh negatively regulates GPVI-dependent aIIbb3
activation, but that at high concentrations this inhibition can be
overcome. Interestingly however, platelet aggregation was not
affected at either of these concentrations of CRP (Fig. 4B), nor was
collagen-induced aggregation affected (Fig. 4C).
PKCh negatively regulates thrombus formation in vitro
Since PKCh2/2 aggregated normally, despite increased aIIbb3
activation and a-granule secretion, we investigated whether the
role of PKCh might become more apparent during thrombus
formation in the more physiological setting of flow conditions.
Anticoagulated whole blood was passed over a collagen-coated
Figure 2. PKCh positively regulates filopodia number when platelets spread on fibrinogen. Platelets were deposited on fibrinogen-
coated coverslips in a live-cell chamber for 45 min and visualized by DIC microscopy. Five fields of view were selected at random, and one such field
is shown in (A) for WT and PKCh2/2 platelets. In (B), filopodia number was counted for each visible platelet and the number of platelets with none,
few (1–2), some (3–5) or many (6 or more) filopodia were expressed as a proportion of the total number of platelets in view. Shown are combined
data from three independent experiments. Bar indicates 10 mm.
doi:10.1371/journal.pone.0003277.g002
Figure 3. PKCh negatively regulates a-granule secretion. A: Washed platelets from WT or KO mice were stimulated with CRP (1 or 5 mg/ml) in
the presence of FITC-labelled anti-P-selectin antibody for 15 minutes, and surface labelling measured by flow cytometry. Representative histograms
are shown in A(i) (1 mg/ml), and fold-increase in geometric mean compared to unstimulated platelets is shown in A(ii) (mean6SEM; n= 8). B, C: ATP
secretion from dense granules in response to CRP (B) or collagen (C) was monitored in a luminometer using the luciferin-luciferase reaction. Data are
presented as mean6SEM (n= 4).
doi:10.1371/journal.pone.0003277.g003
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coverslip through a parallel-plate flow chamber at a shear rate of
1000 s21, and thrombi observed under phase contrast after 4 min.
Figure 5 shows that platelets from WT mice formed substantial
thrombi on the collagen surface, However, platelets from PKCh2/
2 formed significantly larger thrombi, suggesting that the negative
role of PKCh is necessary to restrict thrombus size under flow
conditions.
Discussion
PKC activation is generally considered to positively regulate
platelet signalling, since platelet activation is inhibited by broad-
spectrum PKC inhibitors, and PKC activators can enhance
platelet activation. However, here we show that the role of PKCh
is more complicated than this, as it negatively regulates a-granule
secretion and inside-out signalling to integrin aIIbb3, yet positively
regulates outside-in integrin signalling. In the absence of PKCh,
thrombus formation was markedly enhanced, suggesting that
PKCh restricts thrombus size.
First, we observed a significant reduction in PKCh2/2 platelet
adhesion and reduced spreading on fibrinogen compared to WT
platelets, in agreement with Soriani et al. [24]. Interestingly,
Soriani’s study showed an approximately 50% reduction in spread
platelet surface area whereas our study only showed a 13%
reduction. This apparent quantitative (though not qualitative)
discrepancy could result from technical differences between our
experiments. We used DIC microscopy to image platelet spreading,
and the surface area of platelets was measured by manually
outlining each cell (approximately 25 mm2). Another study by
McCarty et al [26] that used this approach saw a similar surface
area. In both McCarty’s study and ours, mouse platelets rarely
formed large lamellipodia when spreading on fibrinogen, (in
contrast to human platelets, which form full lamellipodia on
fibrinogen) and filopodia were still apparent even after 45 minutes.
In contrast, Soriani et al. [24] measured the surface area by confocal
microscopy of rhodamine-phalloidin stained platelets, and reported
a much lower surface area (approximately 8 mm2). Rather than
measure the surface area directly, this method measures F-actin
coverage, perhaps suggesting that PKCh regulates actin polymer-
ization. WT platelets spread on fibrinogen and imaged using this
method do not appear to exhibit the spiky morphology we and
others [26,27] observe using DICmicroscopy. Our analysis suggests
that PKCh positively regulates filopodia formation, since a smaller
proportion of PKCh2/2 platelets showed many (.5) filopodia
compared to WT. Regardless of these quantitative differences, both
of our studies qualitatively agree that PKCh is a positive regulator of
outside-in signalling by integrin aIIbb3.
In contrast, PKCh negatively regulates GPVI-induced aIIbb3
activation. The selective GPVI agonist, CRP, induced a
concentration-dependent increase in binding of JON/A, an
Figure 4. PKCh negatively regulates CRP-stimulated integrin aIIbb3 activation but not platelet aggregation. A: Washed platelets from
WT or KO mice were stimulated with CRP (1 or 5 mg/ml) in the presence of PE-labelled JON/A for 15 minutes, and surface labelling measured by flow
cytometry. Representative histograms are shown in (i) (1 mg/ml), and fold-increase in geometric mean compared to unstimulated platelets is shown
in (ii) (mean6SEM; n= 8). B, C: Platelet aggregation in response to CRP (B) or collagen (C) was monitored by turbidometry. Traces, shown in B(i) and
C(i), are representative of at least three separate experiments. Mean extent of aggregation at 5 min (6SEM; n = 3) is shown in B(ii) and C(ii), for CRP
and collagen, respectively.
doi:10.1371/journal.pone.0003277.g004
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activation state-specific aIIbb3 antibody. In PKCh
2/2 platelets this
was markedly enhanced compared to WT at an intermediate
concentration of CRP, though not at a higher concentration,
suggesting that PKCh reduces expression of active aIIbb3 on the
platelet surface, although inhibition can be overcome as agonist
stimulation increases. It has been previously reported that PKCh
does not regulate aIIbb3 activation in response to ADP or
AYPGKF [24], both of which act through G protein-coupled
receptors, suggesting that the regulatory role of PKCh may be
specific to GPVI signalling.
CRP-induced aggregation was not affected by the absence of
PKCh, however. Similarly, collagen-induced aggregation was also
the same in WT and PKCh2/2 platelets. The lack of any effect on
the rate or extent of aggregation was surprising, especially in
response to 1 mg/ml CRP. At this concentration, the rate of
aggregation was submaximal and yet the extent of integrin
activation strongly enhanced. It might be expected, therefore, that
the increased integrin activation would accelerate aggregation.
However, since the extent of aggregation in response to 1 mg/ml
CRP was almost maximal, further enhancement of aIIbb3 in
PKCh2/2 platelets can have little further effect. The apparent
disparity between absolute levels of integrin activation and extent of
aggregation highlights the large level in integrin reserve believed to
exist in platelets. b3
+/2 platelets, with only 50% of the WT levels of
b3 on their surface, have almost identical bleeding times and
aggregation responses to PMA, ADP, thrombin and arachidonic
acid compared to WT platelets [28]. In like manner, although WT
platelets show approximately 50 % less integrin activation than
PKCh2/2 platelets at 1 mg/ml CRP, we should not expect this
necessarily to relate to a difference in the extent of aggregation.
PKCh also negatively regulates a-granule secretion, although no
difference in dense granule secretion was observed. This suggests
that the release of different platelet granules is regulated by distinct
mechanisms. The PKC family in general is a critical positive
regulator of platelet granule secretion [2,10,11], although this
positive function is likely to be mediated through conventional
(Ca2+-dependent) isoforms [5,10,11]. Thus, it appears that the
different PKC isoforms have contrasting roles in platelet a-granule
secretion: PKCa is critically required for a-granule secretion, and
PKCh acts to counter this action. PKCa is also critically important
for dense granule secretion, which is not countered by PKCh. It
has been suggested that PKCd, closely related to PKCh, may
negatively regulate GPVI-dependent dense granule secretion [5].
This interpretation was based on the use of rottlerin, a supposedly
specific PKCd inhibitor (though several PKCd-independent
targets have been reported [29–31]). However, we have previously
reported that rottlerin enhances GPVI-dependent dense granule
release even in PKCd2/2 mice [13]. Thus, negative regulation of
GPVI-dependent dense granule release does not appear to be
mediated by either PKCd or PKCh.
PKCh negatively regulates thrombus formation under flow over
a collagen-coated surface. Binding to collagen activates GPVI,
leading to integrin aIIbb3 activation, which is enhanced in
PKCh2/2 platelets. The increased number of adhesive contacts
between platelets may accelerate the growth of the thrombus.
Thus, negative regulation of inside-out signalling by PKChmay be
an important brake on thrombus growth at a site of injury. This
effect is in contrast to the lack of effect seen in aggregation,
highlighting the importance of physiological flow conditions [32].
In standard aggregometry, platelets exhibit a very large integrin
reserve, whereas under flow, with higher shear force on any
platelet-platelet interactions, integrin activation may be a limiting
factor. Increased aIIbb3 activation would therefore enhance
thrombus growth. This effect may be partially countered by the
slightly reduced platelet adhesion to fibrinogen and reduced
subsequent spreading, perhaps leading to fewer platelet-platelet
contacts. Given the large effect on integrin activation compared to
the smaller effect on spreading, however, the balance of these
appears to favour increased thrombus size in PKCh2/2 platelets.
In summary, we have shown that PKCh negatively regulates
GPVI-dependent inside-out signalling, in contrast to the positive
role generally ascribed to the PKC family in general. Although
enhanced integrin aIIbb3 activation does not lead to increased
aggregation in an aggregometer tube, PKCh2/2 platelets display
enhanced thrombus formation on collagen under flow, suggesting
that, under more physiological conditions, the regulatory role of
PKCh may restrict thrombus size. This may impact on the clinical
safety of PKCh inhibitors.
Figure 5. PKCh negatively regulates thrombus formation on collagen under flow in vitro. Whole blood was passed over a collagen-coated
coverslip at 1000 s21 for four minutes then observed by phase contrast microscopy (A). Surface coverage was measured and is shown in B as
mean6SEM for three independent experiments. Bar indicates 10 mm.
doi:10.1371/journal.pone.0003277.g005
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